Clinical trial NCT00317200: A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
Official title: Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Lead sponsor: Hoosier Cancer Research Network
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
name: Walther Cancer Institute
First posted: 2006-04-24
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Improvements in therapy for relapsed SCLC are much needed. Paclitaxel has been previously tested and found to have significant single agent activity in relapsed SCLC, including in refractory patients. Angiogenesis plays an important role in SCLC, increased VEGF levels are associated with worse outcomes. Bevacizumab, a monoclonal antibody to VEGF, increase response rates and survival when combined with chemotherapy agents compared with the chemotherapy agent alone in NSCLC, breast cancer, and colorectal cancer. Paclitaxel plus bevacizumab, in the dose and schedule proposed in this study, improves response rates and progression free survival compared with paclitaxel alone in women with metastatic breast cancer. Therefore, we will be testing the safety, feasibility, and efficacy of this regimen in patients with chemosensitive relapsed SCLC.

Detailed description: OUTLINE: This is a multi-center study.

Paclitaxel 90 mg/m2 IV infusion over 1 hour days 1, 8 and 15 of 28 day cycle

Plus

Bevacizumab 10 mg/kg on days 1 and 15 of 28 day cycle.

* 1 cycle = 28 days (4 weeks)
* Disease assessments will be performed per RECIST every other cycle
* After a minimum of 4 cycles or a maximum of 6 cycles of combination chemotherapy, bevacizumab monotherapy may continue until disease progression or intolerable side effects

ECOG Performance Status 0 or 1

Hematopoietic:

* White blood cell count \> 3,000 mm3
* Absolute neutrophil count (ANC) \> 1,500 mm3
* Platelet count \> 100,000 mm3
* International normalized ration (INR) of prothrombin time ≤ 1.2
* PTT no more than 5 seconds longer than the ULN

Hepatic:

* Bilirubin \< 1.5 x ULN
* Aspartate aminotransferase (AST, SGOT) \< 2.5 x ULN

Renal:

* Urine protein:creatinine ratio \<1.0

Cardiovascular:

* No history of myocardial infarction or angina pectoris/anginal equivalent in the last 6 months. Note: The patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months.
* No history of uncontrolled congestive heart failure or uncontrolled hypertension

Eligibility criteria: Inclusion Criteria:

* Histologic or cytologic proof of small cell lung cancer
* Chemo-sensitive disease defined as relapsed after 60 days from completion of first line chemotherapy.
* Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy.
* Must have received treatment with at least 1 but not more than 2 prior chemotherapy regimens. (At least one regimen must contain a platinum agent. Previous treatment with irinotecan is allowed.)
* Prior radiation therapy must be completed at least 21 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to ≤ grade 1 or baseline prior to registration.
* Prior cancer treatment must be completed at least 21 days prior to being registered for protocol therapy and the subject must have recovered from the acute toxicity effects of the regimen prior to registration.

Exclusion Criteria:

* No treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
* No history or radiographic evidence of CNS involvement by head CT or MRI within 42 days prior to registration.
* No history of seizures, transient ischemic attack or stroke.
* No clinically significant infections as judged by the treating investigator.
* No other active cancer except SCLC.
* No prior treatment with topoisomerase I inhibitor.
* No contraindications to the use of paclitaxel or bevacizumab as per the investigator's clinical judgment.
* Must not have grade 3 or greater peripheral neuropathy.
* Must not have had major surgical procedure, open biopsy, or significant traumatic injury within 28 days of being registered for protocol therapy.
* No anticipation of need for major surgical procedure during the course of the study.
* Patients may not have had a minor surgical procedure, placement of an access device or fine needle aspiration within 7 days prior to being registered for protocol therapy.
* No evidence of bleeding diathesis or coagulopathy.
* No history of deep vein thrombosis or pulmonary embolism.
* No full dose/therapeutic anticoagulation with either low molecular weight heparin or unfractionated heparin or coumadin within 10 days prior to registration.
* Patients must not have been using aspirin (\>325 mg/day) or another nonsteroidal anti-inflammatory medications known to inhibit platelet function on a daily basis within 10 days prior to registration on study.
* Patients must not be using any of the following drugs known to inhibit platelet function within 10 days prior to registration: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal).
* Patients must not have a current non-healing wound or fracture.
* Patients must not have a history of or current hemoptysis.

Primary outcomes:
measure: To determine progression free survival(PFS) of this regimen in patients with chemosensitive relapsed small cell lung cancer (SCLC).
timeFrame: 18 months
Secondary outcomes:
measure: To determine the response rate of the combination of paclitaxel and bevacizumab with chemosensitive SCLC.
timeFrame: 18 months
measure: To determine the toxicity of the combination of paclitaxel and bevacizumab in patients with SCLC.
timeFrame: 18 months
measure: To determine overall survival.
timeFrame: 18 months
measure: To assess VEGF polymorphisms in the study population.
timeFrame: 18 months
Other outcomes:
Locations:
city: Springdale
country: United States
facility: Highlands Oncology Group
state: Arkansas
city: Galesburg
country: United States
facility: Medical & Surgical Specialists, LLC
state: Illinois
city: Bloomington
country: United States
facility: Cancer Care Center of Southern Indiana
state: Indiana
city: Evansville
country: United States
facility: Oncology Hematology Associates of SW Indiana
state: Indiana
city: Fort Wayne
country: United States
facility: Fort Wayne Oncology & Hematology, Inc
state: Indiana
city: Goshen
country: United States
facility: Center for Cancer Care at Goshen Health System
state: Indiana
city: Indianapolis
country: United States
facility: Indiana University Cancer Center
state: Indiana
city: Indianapolis
country: United States
facility: Quality Cancer Center (MCGOP)
state: Indiana
city: Indianapolis
country: United States
facility: Community Regional Cancer Center
state: Indiana
city: Lafayette
country: United States
facility: Arnett Cancer Care
state: Indiana
city: Muncie
country: United States
facility: Medical Consultants, P.C.
state: Indiana
city: New Albany
country: United States
facility: Center for Cancer Care, Inc., P.C.
state: Indiana
city: South Bend
country: United States
facility: Northern Indiana Cancer Research Consortium
state: Indiana
city: St. Louis
country: United States
facility: Siteman Cancer Center
state: Missouri
city: Omaha
country: United States
facility: Methodist Cancer Center
state: Nebraska
city: Philadelphia
country: United States
facility: Pennsylvania Oncology-Hematology Associates
state: Pennsylvania
city: Rockledge
country: United States
facility: Fox Chase Cancer Center Extramural Research Program
state: Pennsylvania
Study officials:
affiliation: Hoosier Oncology Group, LLC
name: Nasser Hanna, M.D.
role: STUDY_CHAIR
References:
citation: Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010 Dec;5(12):2008-11. doi: 10.1097/JTO.0b013e3181f77b6e.